Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer.
Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects.
Recently, Nuvation Bio announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society for Medical Oncology (ESMO). Analysis showed that its small molecule taletrectinib, a new highly selective ROS1/NTRK kinase inhibitor, can cross the patient's blood-brain barrier to treat brain metastases, and nearly 90% of patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who received treatment had tumor shrinkage. In patients who had never been treated with tyrosine kinase inhibitors (TKIs), disease remission was sustained for nearly 4 years. Nuvation Bio plans to submit a new drug application (NDA) for the drug to the FDA in the fourth quarter of this year. Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Search 
+86 21 5895 0110 
